Powerbase - User contributions [en]

Mutual Recognition Agreements

2008-03-25T12:36:52Z

STUART KING:

As part of [[Globalisation: European Commission and the Pharmaceutical Industry]]

This is the activity of European Commission whereby in the context of the EU pharmaceutical industry, MRAs faciliate the international trading of pharmaceutical products. Essentially, MRAs set out the conditions between the EU and other countries in the trading and promoting of pharmaceuticals. The Commission's pharmaceutical unit play an important role in actively promoting the trading of such products between the EU and countries on a global scale, e.g. Canada, the US, Australia, New Zealand, Switzerland and Japan. <ref> European Commission [http://ec.europa.eu/enterprise/pharmaceuticals/mra/index.htm MRA] Accessed 1/03/08 </ref> <ref> European Commission [http://ec.europa.eu/enterprise/international/index_en.htm Mutual recognition agreements] Accessed 1/03/08 </ref> <ref> European Commission [http://ec.europa.eu/enterprise/pharmaceuticals/mra/doc/statusreport20030717 Pharmaceuticals: regulatory framework and market authorisations.pdf] Accessed 1/03/08 </ref>

==Notes==

<references/>

TRIPS Agreement

2008-03-25T12:22:15Z

STUART KING:

As part of [[Globalisation: European Commission and the Pharmaceutical Industry]]

The 'Agreement on trade-related aspects of intellectual property rights'is an international agreement which the [[World Trade Organisation]] administrates. Various global constituencies have agreed to the patenting or copyright laws covering intellectual properties, i.e. trademarks. <ref> World Trade Organisation [http://www.wto.org/english/tratop_e/trips_e/intel1_e.htm TRIPS: what are intellectual property rights?] Accessed 19/03/08 </ref>

=='''Notes'''==

<references/>

TRIPS Agreement

2008-03-23T12:08:24Z

STUART KING:

[[Globalisation: European Commission and the Pharmaceutical Industry]]

The 'Agreement on trade-related aspects of intellectual property rights'is an international agreement which the [[World Trade Organisation]] administrates. Various global constituencies have agreed to the patenting or copyright laws covering intellectual properties, i.e. trademarks. <ref> World Trade Organisation [http://www.wto.org/english/tratop_e/trips_e/intel1_e.htm TRIPS: what are intellectual property rights?] Accessed 19/03/08 </ref>

=='''Notes'''==

<references/>

TRIPS Agreement

2008-03-23T12:08:05Z

STUART KING:

TRIPS Agreement

2008-03-23T12:07:51Z

STUART KING:

Globalisation:Billy Tauzin

2008-03-20T16:53:50Z

STUART KING:

The Current President and Chief Executive Officer of PHRMA[[Image:Billy_tauzin.jpg|frame|Courtesy of PHRMA website]]

<ref> About Billy http://www.phrma.org/about_billy/ Accessed 2nd March 2008 </ref>

=='''References'''==

<references/>

Billy Tauzin

2008-03-20T16:52:44Z

STUART KING:

Billy Tauzin

2008-03-20T13:00:31Z

STUART KING:

Mutual Recognition Agreements

2008-03-19T17:21:18Z

STUART KING:

[[Globalisation: European Commission and the Pharmaceutical Industry]]

This is the activity of European Commission whereby in the context of the EU pharmaceutical industry, MRAs faciliate the international trading of pharmaceutical products. Essentially, MRAs set out the conditions between the EU and other countries in the trading and promoting of pharmaceuticals. The Commission's pharmaceutical unit play an important role in actively promoting the trading of such products between the EU and countries on a global scale, e.g. Canada, the US, Australia, New Zealand, Switzerland and Japan. <ref> MRA http://ec.europa.eu/enterprise/pharmaceuticals/mra/index.htm Accessed 1/03/08 </ref> <ref> Mutual recognition agreements http://ec.europa.eu/enterprise/international/index_en.htm Accessed 1/03/08 </ref> <ref> Pharmaceuticals: regulatory framework and market authorisations http://ec.europa.eu/enterprise/pharmaceuticals/mra/doc/statusreport20030717.pdf Accessed 1/03/08 </ref>

==Notes==

<references/>

TRIPS Agreement

2008-03-19T17:19:42Z

STUART KING:

User talk:Allistair Gray

2008-03-19T15:13:51Z

STUART KING: /* Bawbag */

hello

hello

Some sources on BAA and the commission for Africa:
http://www.corporatewatch.org.uk/?lid=2688
http://www.corporatewatch.org.uk/?lid=1535
http://www.corporatewatch.org.uk/?lid=1279
http://www.ukwatch.net/article/alternative_commission_on_africa
http://www.spinwatch.org/content/view/147/8/
http://www.ukwatch.net/article/our_corporate_interest
http://redpepper.blogs.com/g8/2005/07/alternative_afr.html
http://commentisfree.guardian.co.uk/calestous_juma/2007/05/blair_the_critics_are_wrong.html
http://www.zmag.org/content/showarticle.cfm?ItemID=7852

Hi, you need to add the name of the organisation before the title 'Full list of members'

OK?
--[[User:David|David]] 17:06, 13 March 2008 (UTC)

TRIPS Agreement

2008-03-19T12:08:45Z

STUART KING:

The 'Agreement on trade-related aspects of intellectual property rights'is an international agreement which the [[World Trade Organisation]] administrates. Various global constituencies have agreed to the patenting or copyright laws covering intellectual properties, i.e. trademarks. <ref> World Trade Organisation [http://www.wto.org/english/tratop_e/trips_e/intel1_e.htm TRIPS: what are intellectual property rights? </ref>

=='''References'''==

<references/>

Tiziana Palmisano

2008-03-18T16:05:02Z

STUART KING:

Horizontal policy issues

Irene Sacristan Sanchez

2008-03-18T16:04:45Z

STUART KING:

Deputy Head of Unit

Martin Terberger

2008-03-18T15:59:00Z

STUART KING:

Martin Terberger

2008-03-18T15:58:15Z

STUART KING: /* Notes */

Head of Unit of European Commission Phamaceuticals Unit[[Image:Terberger_martin.jpg|frame|Source:]]

In 1979 Martin Terberger qualified as a vet at Justus Liebig University, Giessen and the Free University of Berlin, whereby he worked as a vet for 5 years whilst stdying for a doctorate in veterinary science in 1988. Subsequently Terberger then joined the German Ministry of Agriculture in 1990 before joining the European Commission in 1995. With his wealth of expertise in DG agriculture, he was appointed to the European Commission’s DG Enterprise. Having worked there for a number of years, Terberger finally became head of unit F1 (pharmaceuticals) in 2005. <ref> IFAH [http://www.ifahsec.org/Europe/events/docs/Martin%20Terberger%20biography.doc Martin Terberger] Accessed 04/03/08 </ref>

=='''References'''==

<references/>

Martin Terberger

2008-03-18T15:57:57Z

STUART KING:

Communication on the future of pharmaceuticals

2008-03-04T15:42:12Z

STUART KING:

Variations regulations

2008-03-04T15:41:23Z

STUART KING:

Standing committee

2008-03-04T15:40:43Z

STUART KING:

Pharmaceutical committee

2008-03-04T15:39:59Z

STUART KING:

Good manufacturing practice (GMP)

2008-03-04T15:39:19Z

STUART KING:

Medicines for children

2008-03-04T15:37:09Z

STUART KING:

Mutual Recognition Agreements

2008-03-04T15:36:50Z

STUART KING:

This is the activity of European Commission whereby in the context of the EU pharmaceutical industry, MRAs faciliate the international trading of pharmaceutical products. Essentially, MRAs set out the conditions between the EU and other countries in the trading and promoting of pharmaceuticals. The Commission's pharmaceutical unit play an important role in actively promoting the trading of such products between the EU and countries on a global scale, e.g. Canada, the US, Australia, New Zealand, Switzerland and Japan. <ref> MRA http://ec.europa.eu/enterprise/pharmaceuticals/mra/index.htm Accessed 1/03/08 </ref> <ref> Mutual recognition agreements http://ec.europa.eu/enterprise/international/index_en.htm Accessed 1/03/08 </ref> <ref> Pharmaceuticals: regulatory framework and market authorisations http://ec.europa.eu/enterprise/pharmaceuticals/mra/doc/statusreport20030717.pdf Accessed 1/03/08 </ref>

==Notes==

<references/>

Mutual Recognition Agreements (MRA)

2008-03-04T15:36:20Z

STUART KING:

Maximum Residue Limits of veterinary medicinal products in foodstuffs of animal origin(MRL)

2008-03-04T15:35:36Z

STUART KING:

The Community Register of Medicinal Products

2008-03-04T15:33:10Z

STUART KING:

Essentially, the Unit maintains a register regarding pharmaceuticals which are used for human,orphan (rare) and veterninary use. A record is kept of all pharmaeuticals which are active in the EU, i.e. products which have been approved of a legible status by the EU. The register also records those products which have been withdrawn or suspended from trading in the EU; and those which have been refused. <ref> The community Register of medicinal products http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm Accessed 29/02/08 </ref>

==Notes==

<references/>

The Community Register of medicinal products

2008-03-04T15:32:39Z

STUART KING:

Martin Terberger

2008-03-04T12:35:14Z

STUART KING:

Head of Unit of European Commission Phamaceuticals Unit[[Image:Terberger_martin.jpg|frame|Source:]]

In 1979 Martin Terberger qualified as a vet at Justus Liebig University, Giessen and the Free University of Berlin, whereby he worked as a vet for 5 years whilst stdying for a doctorate in veterinary science in 1988. Subsequently Terberger then joined the German Ministry of Agriculture in 1990 before joining the European Commission in 1995. With his wealth of expertise in DG agriculture, he was appointed to the European Commission’s DG Enterprise. Having worked there for a number of years, Terberger finally became head of unit F1 (pharmaceuticals) in 2005. <ref> Martin Terberger http://www.ifahsec.org/Europe/events/docs/Martin%20Terberger%20biography.doc Accessed 04/03/08 </ref>
==Notes==

<references/>

Martin Terberger

2008-03-04T12:21:31Z

STUART KING:

Head of Unit of European Commission Phamaceuticals Unit[[Image:Terberger_martin.jpg|frame|Source:]]

H aving previously being a vet

European Commission

2008-03-03T23:36:04Z

STUART KING:

==Agencies and initiatives==

*[[EU Platform for Action on Diet, Physical Activity and Health]]
*[[Globalisation:European Commission and the Pharmaceutical Industry|EU intervention in the Pharmaceutical Industry and global impacts]]
===Issues===
*[[Water Initiatives in the European Union]]

European Commission

2008-03-03T23:35:28Z

STUART KING: /* Agencies and initiatives */

==Agencies and initiatives==

*[[EU Platform for Action on Diet, Physical Activity and Health]]
*[[Globalisation:European Commission and the Pharmaceutical Industry|Pharmaceutical Industry]]
===Issues===
*[[Water Initiatives in the European Union]]

European Commission

2008-03-03T23:34:48Z

STUART KING: /* Agencies and initiatives */

==Agencies and initiatives==

*[[EU Platform for Action on Diet, Physical Activity and Health]]
*[[Pharmaceutical Industry|Globalisation:European Commission and the Pharmaceutical Industry]]
===Issues===
*[[Water Initiatives in the European Union]]

European Commission

2008-03-03T23:30:46Z

STUART KING: /* Agencies and initiatives */

==Agencies and initiatives==

*[[EU Platform for Action on Diet, Physical Activity and Health]]
*[[Pharmaceutical Industry]]
===Issues===
*[[Water Initiatives in the European Union]]

Communication on the future of pharmaceuticals

2008-03-03T23:20:34Z

STUART KING:

==Notes==

<references/>

Variations regulations

2008-03-03T23:20:25Z

STUART KING:

==Notes==

<references/>

Standing committee

2008-03-03T23:20:20Z

STUART KING:

==Notes==

<references/>

Pharmaceutical committee

2008-03-03T23:20:12Z

STUART KING:

A key activity of the European Commission concerns all those actors involved in the unit or committee meeting up and discussing issues concerning all issues relevant to the other prevailing functions of the unit.

==Notes==

<references/>

Good manufacturing practice (GMP)

2008-03-03T23:20:00Z

STUART KING:

==Notes==

<references/>

Medicines for children

2008-03-03T23:19:15Z

STUART KING:

An intergal practice of the European Commission's pharmaceutical unit is to ensure a good quality of medicinal products for paedriatic use. In response to the incidence of inadequate medicines for children in Europe, the European Commission implemented a proposal on the 29th September 2004. Additionally this legislation seeks to promote the development of paediatric medicines, whereby at the national scale of EU member states have a role to play in providing national incentives for the research and development of such pharmaceuticals. <ref> Regulation on medicines for children http://ec.europa.eu/enterprise/pharmaceuticals/paediatrics/docs/paeds_qa_october_28.pdf Accessed 1/03/08 </ref>

==Notes==

<references/>

Mutual Recognition Agreements (MRA)

2008-03-03T23:18:51Z

STUART KING:

Maximum Residue Limits of veterinary medicinal products in foodstuffs of animal origin(MRL)

2008-03-03T23:18:08Z

STUART KING:

In general an activity of the Commission's Pharmaceutical Unit is to "ensure the protection of consumers against possible harmful effects resulting from the exposure to residues of veterinary medicinal products present in foodstuffs". <ref> MRL http://ec.europa.eu/enterprise/pharmaceuticals/mrl/index.htm Accessed 1/03/08 </ref> By continually reviewing and ammending such regulations, it is the aim of the unit to guarantee a high level of public health protection by ensuring that MRLs meet international standards in trading. In simple terms, the trade of reared animals in the EU are set within MRLS which regulate the exposure they have to veterinary pharmaceuticals. This is to ensure the protection of the welfare for both animals and consumers <ref> Ibid 15 </ref>

==Notes==

<references/>

Orphan Drugs

2008-03-03T23:17:27Z

STUART KING:

Regulating drugs for rare diseases is a carefully monitored process by the unit. A main feature of this is providing guidelines for sponsers on how to apply for orphan medicinal product designation to transfer drugs to the European Medicines Agency (EMEA). This is a step that has not only been taken by the European Commission and the EMEA acting within it; the United States and [[Food and Drug Administration]] (FDA) also have adopted a common applcation that sponsers must fill out in the request to transfer orphan products intended for rare diseases in the EU and US. <ref>
Orphan medicinal products http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/index.htm Accessed 29/02/08 </ref>

==Notes==

<references/>

The Community Register of medicinal products

2008-03-03T23:17:13Z

STUART KING:

Pharmaceutical committee

2008-03-03T23:15:04Z

STUART KING:

Medicines for children

2008-03-03T23:12:33Z

STUART KING:

Mutual Recognition Agreements (MRA)

2008-03-03T23:11:36Z

STUART KING:

Maximum Residue Limits of veterinary medicinal products in foodstuffs of animal origin(MRL)

2008-03-03T23:11:05Z

STUART KING:

Orphan Drugs

2008-03-03T23:09:44Z

STUART KING:

The Community Register of medicinal products

2008-03-03T23:09:01Z

STUART KING: